SurfSpec: Enhancing Off-Target-Agnostic Specificity by Bounding Pocket-Ligand Geometric Mismatch

Off-target protein binding is a major source of adverse effects for small-molecule drugs, yet most structure-based molecular design methods focus on generating selective compounds de novo rather than improving the selectivity of existing, well- characterized drugs. We introduce specificity optimization (SpecOpt), a molecular design task that seeks constrained structural modifications to an existing compound that increase its binding preference for an intended target over known off-targets while preserving its structural identity and drug-like properties. To enable systematic evaluation, we construct a ChEMBL-derived benchmark from compound-target interaction data, identifying intended targets through curated drug-mechanism annotations and off- targets through measured activities. We then develop an agentic framework that docks each compound against its intended target and off-targets, compares the resulting poses through residue-aware atom-protein contacts, and provides these differential interactions to a large language model to propose targeted structural modifications. Candidates are retained only if they satisfy molecular similarity, ADMET, and target-off-target docking selectivity criteria. On 915 compounds, the agent improves the target- off-target binding gap for 84.8% of compounds, shifting the mean gap from -0.72 to +0.47 kcal/mol while maintaining a mean Tanimoto similarity of 0.72 to the starting compounds. Ablation studies identify residue-specific contact information as the critical optimization signal: replacing residue identities with binary contact indicators eliminates improvement on all 29 ablation compounds. These results establish SpecOpt as a distinct molecular design problem and demonstrate residue-aware differential interactions as an effective signal for improving the specificity of existing compounds.

Structure-based drug design increasingly employs LLM agents to iteratively refine ligands against a target pocket, yet a viable ligand must satisfy two often-conflicting objectives---binding affinity and druggability---which single optimization steps rarely improve together. To quantify this difficulty, we introduce two diagnostic metrics: the first measures how often a single edit improves both objectives, and the second measures how often a gain on one objective comes with a loss on the other. Applying these diagnostics to current LLM-agent pipelines exposes a consistent failure mode: the agent performs molecular editing without knowing how the pocket-ligand complex responds to local modifications, thus rarely achieving joint improvement. Inspired by medicinal chemists, who probe the pocket-ligand complex with controlled analog edits before choosing an optimization direction, we propose PROBE, an optimization framework built around edit--response probing. PROBE first decomposes the ligand into editable sites and builds a pocket-specific site map that flags where joint gains are plausible, where the two objectives are likely in tension, and where liability substructures should be changed; it then performs controlled probe edits whose responses are distilled into an EditManual. Guided by the site map and EditManual, PROBE runs an iterative multi-agent optimization loop. On the CrossDocked2020 benchmark, PROBE achieves state-of-the-art performance and substantially mitigates the failure modes exposed by our diagnostics metrics. Codes are in https://github.com/yzf-code/PROBE/tree/main

Dual-target structure-based drug design aims to generate a single ligand together with two pocket-specific binding poses, each compatible with a corresponding target pocket, enabling polypharmacological therapies with improved efficacy and reduced resistance. Existing approaches typically rely on staged pipelines, which either decouple the two poses via conditional-independence assumptions or enforce overly rigid correlations, and therefore fail to jointly generate two target-specific binding modes. To address this, we propose FuseDiff, an end-to-end diffusion model that jointly generates a ligand molecular graph and two pocket-specific binding poses conditioned on both pockets. FuseDiff features a message-passing backbone with Dual-target Local Context Fusion (DLCF), which fuses each ligand atom's local context from both pockets to enable expressive joint modeling while preserving the desired symmetries. Together with explicit bond generation, FuseDiff enforces topological consistency across the two poses under a shared graph while allowing target-specific geometric adaptation in each pocket. To support principled training and evaluation, we derive a dual-target training set and use an independent held-out test set for evaluation. Experiments on the benchmark and a real-world dual-target system show that FuseDiff achieves state-of-the-art docking performance and enables the first systematic assessment of dual-target pose quality prior to docking-based pose search.